Agents and methods for treatment of anxiety disorders
AssigneeYeda Research and Development Co. Ltd.
InventorsMichal Eisenbach-Schwartz, Gil M. Lewitus
Life of this patent
Estimating the term…
Abstract
Peptides derived from CNS-specific antigens, altered peptide ligands (APL) analogues of said peptides, T cells activated by such peptides, poly-YE, and any combination of said agents are useful for prevention, treatment and/or alleviation of anxiety disorders, particularly post-traumatic stress disorder, and for restoring BDNF levels in the brain of an individual after reduction of BDNF expression induced by stress.
Claims16
(canceled)
The method according to claim 8, wherein said agent is a peptide derived from a CNS-specific antigen selected from the group consisting of myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), proteolipid protein (PLP), myelin-associated glycoprotein (MAG), S-100, β-amyloid, Thy-1, a peripheral myelin protein including P0, P2 and PMP22, neurotransmitter receptors, the protein Nogo including Nogo-A, Nogo-B and Nogo-C and the Nogo receptor, and an APL analogue of said peptide.
The method according to claim 8, wherein said anxiety disorder is post-traumatic stress disorder.
(canceled)
A method for prevention, treatment and/or alleviation of an anxiety disorder, comprising administering to an individual in need thereof an effective amount of an agent selected from the group consisting of:
- (a) peptide derived from a CNS-specific antigen;
- (b) an altered peptide ligand (APL) analogue of a peptide of (a);
- (c) T cells activated by a peptide of (a) or (b);
- (d) poly-YE;
- and
- (e) any combination of (a)-(d).
(canceled)
A method for restoring BDNF levels in the brain of an individual after reduction of BDNF expression induced by stress, which comprises administering to an individual in need thereof an effective amount of an agent selected from the group consisting of:
- (a) a peptide derived from a CNS-specific antigen;
- (b) an altered peptide ligand (APL) analogue of a peptide of (a);
- (c) (d) T cells activated by a peptide of (a) or (b);
- (d) poly-YE;
- and
- (e) any combination of (a)-(d).
A method for treatment and/or alleviation of an anxiety disorder, comprising administering to an individual in need thereof an effective amount of an agent selected from the group consisting of:
- (a) peptide derived from a CNS-specific antigen;
- (b) an altered peptide ligand (APL) analogue of a peptide of (a);
- (c) T cells activated by a peptide of (a) or (b);
- (d) poly-YE;
- and
- (e) any combination of (a)-(d).
Dependencies are inferred from the claim text.